The state of Delaware is part of a legal settlement involving the distributor of a drug meant to help curb opioid addiction.
Delaware and other states have reached an agreement with the English company Reckitt Benckiser Group.
The states alleged the pharmaceutical distributor improperly marketed the drug Suboxone, putting a strain on state Medicaid funds.
Suboxone is approved for use by recovering opioid addicts to reduce withdrawal symptoms. Its active ingredient is buprenorphine, an addictive opioid.
The lawsuits accused Reckitt of promoting the sale of Suboxone for medically unnecessary uses, for falsely claiming Suboxone was less susceptible to abuse than similar products and for fraudulent price control practices.
Reckitt will pay a total of $700 million. More than $3 million will go to Medicaid.
Delaware’s share is $1.3 million. The state says that amount will go to its Division of Medicaid and Medical Assistance.
In a statement, Attorney General Kathy Jennings credited Delaware’s Medicaid Fraud Control Unit for the result.
